Multiple SclerosisNCT07504783
A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab
An observational study of Multiple Sclerosis, run by Novartis Pharmaceuticals at 1 site in Switzerland.
Trial summary
The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Multiple Sclerosis
- How many people
- 261 participants
- Where
- 1 siteSwitzerland
- Study dates
- 22 Jan 2026to 30 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Physicians that treat with ofatumumab and MS patients receiving ofatumumab, and who were invited to participate following consultation with their physician.
Who may be able to join
None listed.
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Study Investigating Drivers of Physician and Patient Satisfaction Towards Treatment
The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.
- Conditions
- Multiple Sclerosis
- Keywords
- Ofatumumab, Satisfaction, Patient satisfaction, Physician satisfaction, Relapsing multiple sclerosis
- Medical subject headings
- Multiple Sclerosis, Personal Satisfaction, Patient Satisfaction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| MS Patient Cohort | Adult patients diagnosed with relapsing multiple sclerosis (RMS) who received treatment with ofatumumab, and were invited to participate following a consult with their physician. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number and Percentage of Patients by Patient-reported Level of Satisfaction With Current MS Treatment
Patient's level of satisfaction with current treatment categorized as follows:
- Completely dissatisfied
- Moderately dissatisfied
- Neither dissatisfied nor satisfied
- Moderately satisfied
- Completely satisfied
- Not on any current treatment for MS
Measured: 1 Day
Number and Percentage of Patients by Patient-reported MS Status With Their Current Medication Compared to Previous Medication
MS status, as reported by the patient, categorized as follows:
- Very much better
- Much better
- A little better
- No change
- A little worse
- Much worse
- Very much worse
- Don't know
- No previous medication taken for MS
Measured: 1 Day
Number and Percentage of Patients by Physician-reported Patient Response to Current MS Treatment
How well the patient is responding to current treatment rated by the physician from 1 (very poorly) to 5 (very well).
Measured: 1 Day
Number and Percentage of Patients by Physician-reported Level of Satisfaction With the Patient's Current MS Treatment
Physician's level of satisfaction with patient's current treatment categorized as follows:
- Completely dissatisfied
- Moderately dissatisfied
- Neither dissatisfied nor satisfied
- Moderately satisfied
- Satisfied
- Completely satisfied
Measured: 1 Day
Number and Percentage of Patients Adherent to Current MS Treatment as Reported by the Physician
Adherence, as reported by the physician, categorized as follows:
- Completely adherent
- Mostly adherent
- Somewhat adherent
- A little adherent
- Not at all adherent
- Too early in patient's regimen to tell
- Don't know
Measured: 1 Day
Number and Percentage of Patients by Physician-reported Change in Patient Condition Since Initiation of Current MS Treatment
Change in condition, as reported by the physician, categorized as follows:
- Very much improved
- Much improved
- A little bit improved
- No change
- A little bit worse
- Much worse
- Very much worse
Measured: 1 Day
Secondary outcomes (4)
Number and Percentage of Patients by Factors That Influence How the Patient Rates Current Medication Compared to Previous Medication
Factors influencing how patients rate medication include:
- Frequency of relapses
- Impact on symptoms during relapses
- MS progression
- Convenience (impact on daily routine)
- Side effects
- Route of administration
- Frequency of administration
- Impact on quality of life (e.g. liveliness, social functioning, perceived wellbeing)
- No change / No previous medication for MS taken
- Don't know
Measured: 1 Day
Number and Percentage of Patients by Physician-reported Reason for Current MS Treatment Choice
Measured: 1 Day
Number and Percentage of Patients by Physician-reported Top 5 Reasons for Current MS Treatment Choice
Measured: 1 Day
Number and Percentage of Patients by Physician-reported Main Areas of Improvement for the Patient's Current MS Treatment
Measured: 1 Day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2026
- Study start22 Jan 2026
- Primary completion30 Apr 2026
- Study completion30 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 261 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07504783
- Sponsor's protocol ID
- COMB157G2021
- Status last verified
- Jun 2026
- First submitted
- 26 Mar 2026
- Last updated
- 15 Jun 2026
- Results posted
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study Investigating Drivers of Physician and Patient Satisfaction Towards Treatment
- ClinicalTrials.gov ID
- NCT07504783
- Acronym / sponsor ID
- COMB157G2021
- Conditions
- Multiple Sclerosis
- Keywords
- Ofatumumab, Satisfaction, Patient satisfaction, Physician satisfaction, Relapsing multiple sclerosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 261 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 22 Jan 2026 (actual)
- Primary completion
- 30 Apr 2026 (actual)
- Study completion
- 30 Apr 2026 (actual)
- First posted
- 1 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MS Patient Cohort | – | –Adult patients diagnosed with relapsing multiple sclerosis (RMS) who received treatment with ofatumumab, and were invited to participate following a consult with their physician. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Physicians that treat with ofatumumab and MS patients receiving ofatumumab, and who were invited to participate following consultation with their physician.
Key inclusion criteria (0 listed)
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number and Percentage of Patients by Patient-reported Level of Satisfaction With Current MS Treatment
Time frame: 1 Day
Patient's level of satisfaction with current treatment categorized as follows: * Completely dissatisfied * Moderately dissatisfied * Neither dissatisfied nor satisfied * Moderately satisfied * Completely satisfied * Not on any current treatment for MS
Number and Percentage of Patients by Patient-reported MS Status With Their Current Medication Compared to Previous Medication
Time frame: 1 Day
MS status, as reported by the patient, categorized as follows: * Very much better * Much better * A little better * No change * A little worse * Much worse * Very much worse * Don't know * No previous medication taken for MS
Number and Percentage of Patients by Physician-reported Patient Response to Current MS Treatment
Time frame: 1 Day
How well the patient is responding to current treatment rated by the physician from 1 (very poorly) to 5 (very well).
Number and Percentage of Patients by Physician-reported Level of Satisfaction With the Patient's Current MS Treatment
Time frame: 1 Day
Physician's level of satisfaction with patient's current treatment categorized as follows: * Completely dissatisfied * Moderately dissatisfied * Neither dissatisfied nor satisfied * Moderately satisfied * Satisfied * Completely satisfied
Number and Percentage of Patients Adherent to Current MS Treatment as Reported by the Physician
Time frame: 1 Day
Adherence, as reported by the physician, categorized as follows: * Completely adherent * Mostly adherent * Somewhat adherent * A little adherent * Not at all adherent * Too early in patient's regimen to tell * Don't know
Number and Percentage of Patients by Physician-reported Change in Patient Condition Since Initiation of Current MS Treatment
Time frame: 1 Day
Change in condition, as reported by the physician, categorized as follows: * Very much improved * Much improved * A little bit improved * No change * A little bit worse * Much worse * Very much worse
4 secondary outcomes
Number and Percentage of Patients by Factors That Influence How the Patient Rates Current Medication Compared to Previous Medication
Time frame: 1 Day
Number and Percentage of Patients by Physician-reported Reason for Current MS Treatment Choice
Time frame: 1 Day
Number and Percentage of Patients by Physician-reported Top 5 Reasons for Current MS Treatment Choice
Time frame: 1 Day
Number and Percentage of Patients by Physician-reported Main Areas of Improvement for the Patient's Current MS Treatment
Time frame: 1 Day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
RecruitingPhase 2
Efgartigimod for the Treatment of Acute Optic Neuritis
Optic Neuritis
Active, not recruitingPhase 3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 3
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Multiple Sclerosis
Active, not recruitingObservational study
Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
Relapsing Multiple Sclerosis
Not yet recruiting
Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by Novartis Pharmaceuticals at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number and Percentage of Patients by Patient-reported Level of Satisfaction With Current MS Treatment (time frame: 1 Day). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.